There are many patient groups who may refuse blood products; the most well known amongst them is the Jehovah's Witness faith. Treatment of anaemia and bleeding in such patients presents a challenge to medical, anaesthetic, and surgical teams. This review examines the perioperative issues and management of Jehovah's Witnesses. The history and beliefs of Jehovah's Witnesses are outlined together with their impact on ethics and the law, and different management options throughout the perioperative period are discussed.
among them eats any blood, I will set my face against that person who eats blood and will cut him off from among his people.' (iii) Acts 15:29, ' . . . that you abstain from what has been sacrificed to idols, and from blood, and from what has been strangled, and from sexual immorality. If you keep yourselves from these, you will do well. ' Jehovah's Witnesses believe that human blood is sacred and a potential vector for sin, whereas Christ's blood is Holy and is the only blood that can redeem them. 5 Jehovah's Witnesses separate blood into four major components, namely red cells, white cells, platelets, and plasma, which must not be 'consumed' in any circumstance, because they may irreversibly compromise their soul. 15 The evolving nature of transfusion medicine has led to modifications of the position of Jehovah's Witnesses on what may be deemed acceptable. The Watchtower Society (WTS) states that the use of blood fractions is a personal conscientious decision. A reader's justification was published in The Watchtower in 1990 stating that in a 'natural setting' blood fractions ( plasma proteins and bilirubin) move between mother and fetus; and therefore, other minor fractions could potentially be viewed as acceptable. 16 Table 1 outlines the variable acceptability of different blood products amongst Jehovah's Witnesses.
Ethical and legal considerations Bioethics
While one can argue that there is no universal bioethic, in general it is accepted that Beauchamp and Childress' four principles 17 are a sound basis on which an ethical problem can be assessed. Each component is equally weighted and to be followed, unless it conflicts with the others.
(i) Respect for autonomy, including competence, best interests, quality of life and contextual factors, such as religious background; although Muramoto 18 suggests that the individual's wishes are of primary importance and religious considerations should be secondary. (ii) Beneficence (acting in a way to 'do good' for the patient), taking into account the potential psychosocial ramifications for a Jehovah's Witness regarding transfusion. 18 (iii) Non-maleficence; avoidance of causing harm disproportionate to the benefit of treatment. (iv) Justice, including the legal position and human rights.
For the purposes of this article, the focus has been kept on the UK, with illustrative examples from elsewhere to highlight the varying situation in other countries.
Capacity and consent
Medical consent is a decision or agreement to allow an intervention and is not a single event but a continuously evolving process. The ability to make such a decision is defined as capacity. This must be informed and free from duress, which may seem difficult given variations in Jehovah's Witness blood education and the presence of family members or Jehovah's Witness elders during consultations. Adults are assumed to have capacity until proved otherwise and have 'the right to make decisions that others might think are unwise' 19 22 proposes the following four competing issues for children less than 16 yr of age: (i) capacity for consent; (ii) parental authority; (iii) prevailing view in the event of dispute between parent and child; and (iv) power of the court. Similar practices to Gillick competence have been adopted in Australia, Canada, New Zealand, and in certain states of America with the 'mature minor doctrine'. If consent is refused, an application to the High Court for a 'specific issue order' can be made (i.e. parental authority is removed and the procedure may go ahead). If there is not enough time for such an application, then doctors are empowered to act in the 'best interest' of the patient, and blood may be given. 23 
The law
The legal situation surrounding consent for medical interventions among Jehovah's Witnesses is complex and can vary significantly between countries. In his conclusion to the Re T Court of Appeal case, Lord Donaldson of Lymington highlights an important principle: 'What matters is that the doctors should consider whether at that time he had a capacity which was commensurate with the gravity of the decision. The more serious the decision, the greater the capacity required'. 24 The Re T case highlights that fact that next of kin have no legal right to consent or to refuse consent. 24 Administration of blood products against the wishes of a competent patient is a potentially criminal act subject to prosecution. In 1990, Canadian physicians were successfully sued after administering blood transfusions disregarding a Jehovah's Witness's beliefs.
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Two 19th century cases form the basis of current legal precedent regarding children in the UK: (i) the Poor Law Amendment Act 26 of 1868 states that parents 'neglecting their children in various ways' (including refusal of medical treatment) may be criminally liable; and (ii) in the case of the Queen vs Robert Downes 27 in 1875, Downes was convicted of manslaughter after not seeking medical opinion or treatment (an action based on religious objections), which was felt ultimately led to the death of his son. Today, parents have the right and duty to give proxy consent for medical interventions, 22 although this is not necessarily absolute; the court has prevailing control in terms of consent in acting in the child's best interests.
Blood refusal cards
Introduced by the WTS in the 1970s, blood refusal cards are carried in the same way as organ donor cards. There are conflicting legal cases surrounding informed consent and their validity, 25 28 because of the accompanying WTS literature, which highlights transfusion risks while neglecting potential benefits. Should the card's validity be doubted in emergency situations, some recommend treating in the patient's best interest and administering blood. 29 
Advance directives
These are legally binding documents outlining treatments an individual would not consent to in the future, should they lack capacity (outlined by the Mental Capacity Act 2005). 19 They can be made by anyone more than 18 yr of age (16 yr in Scotland) and are usually kept by the patient's general practitioner, family, or friends. In order to be valid, the following provisos must be met: (i) the individual must have capacity at the time of signing; (ii) the directive must be signed with a witness present; and (iii) the directive must must specify the decision applied to a specific treatment if the individual's life is at risk. If any of these conditions is not met, the directive may be invalid. 29 
Staff
We should also be mindful of the potential profound psychological consequences on the multidisciplinary team where significant morbidity or mortality may result from the restrictions placed on their practice by a patient's beliefs, especially when they may have their own ethical objections in Jehovah's Witness treatment. Provided the clinical situation allows (i.e. elective and non-emergent), alternative arrangements should be made with clinicians who are prepared to be involved. 30 31 These scenarios highlight the need for a full team briefing before surgery and the possible need for counselling after surgery. 29 An approach to Jehovah's witness consultations or preoperative assessment
While we present this as a framework for management of Jehovah's Witnesses, it is important to note that the principles of patient blood management are universal and should be applied to all patients. In Jehovah's Witnesses, the approach depends on whether the scenario is an elective or emergency setting. We outline frameworks for each in Table 2 .
Perioperative management
The first step in managing a surgical patient who refuses transfusion is location. Elective surgery should proceed only if the centre has the facility for all elements of patient management. Jehovah's Witnesses (and other patients who refuse transfusion) require a holistic approach across the whole perioperative period (although in elective patients much of the focus will be in preoperative optimization). We outline the specialities that may be involved in their care and the various interventions that can be used in Table 3 . There are four specific aims: (i) to minimize blood loss; to optimize oxygen delivery and consumption; (iii) to enhance haemoglobin (Hb) synthesis and erythropoiesis; and (iv) to correct coagulation defects and promote haemostasis. These should be followed in conjunction with more general aims, such as the optimization of co-morbidities and nutritional state.
Minimization of blood loss
Blood loss increases morbidity, and Spence and colleagues 32 showed that mortality throughout the perioperative period increases with blood loss >500 ml irrespective of the preoperative Hb concentration, which is why cessation of blood loss is a top priority.
General principles
If blood loss is suspected in a Jehovah's Witness patient, prompt and senior assessment and intervention is essential. 30 31 This must include a rationalized approach to ordering blood tests to limit phlebotomy; 33 the use of a paediatric or micro-sample tube and microanalysers has been shown to be effective. 33 34 These patients also require a close degree of monitoring; after surgery, this may involve high-dependency level care.
Medical care
Whilst optimizing other medical co-morbidites, it is important to anticipate and treat other potential vectors of blood loss, for example: (i) proton pump inhibitors for gastrointestinal ulceration; 35 (ii) progesterone for menstruation; 36 and (iii) endoscopic or interventional radiological treatments for other types of medical bleeding. 35 37 Anaesthetic care
General interventions that may be beneficial include the following.
(i) Positioning needs to be taken into account because of potential cardiovascular effects that may increase bleeding risk by altering preload, cardiac output, and peripheral vascular resistance. (ii) The mode of ventilation is important. While mechanical ventilation may avoid hypercapnia and an associated increase in bleeding, it reverses intrathoracic pressure, which acts to decrease venous return and potentially increase venous blood loss. (iii) In the elective setting, hypothermia should be avoided to prevent the potential for coagulopathy and blood loss.
Specific interventions that may be beneficial include the following.
(i) Acute normovolaemic haemodilution involves the removal of blood followed by rapid infusion of colloid or crystalloid to restore plasma volume. Any surgical blood loss will therefore have a lower haematocrit, and previously stored blood can then be reinfused. However, this may not be acceptable to Jehovah's Witnesses unless a closed circuit is used, 38 39 despite some evidence to suggest that it may reduce the risk of allogeneic transfusion. 40 41 (ii) Acute hypervolaemic haemodilution is a simpler, acceptable alternative, which does not involve removal of the patient's blood. Despite small numbers, a study by Entholzner and colleagues 42 showed no statistically significant differences between acute normovolaemic haemodilution and acute hypervolaemic haemodilution. (iii) Hypotensive anaesthesia is defined as a systolic blood pressure of 80-90 mm Hg, a mean arterial pressure of 50-65 mm Hg, or a 30% reduction of baseline mean arterial pressure. 43 It has been used in a variety of surgical specialties and patient populations (including Jehovah's Witnesses) 44 45 as a way of reducing perioperative blood loss and improving surgical field visibility. Degoute 43 suggests that remifentanil (as part of a balanced general anaesthetic) or epidural anaesthesia are the two most satisfactory techniques. (iv) Regional and central neuraxial anaesthesia, when compared with general anaesthesia, are associated with reduced estimated blood loss and postoperative transfusion requirement. 46 47
Surgical care
The key principle is meticulous haemostasis. 30 Other considerations include surgical technique (endoscopic or laparoscopic), use of diathermy, 48 ultrasonic scalpels, 48 collagen or cellulose pads (e.g. Kaltostat), 49 and fibrin glues and sealants (e.g. Tisseal). 50 When surgery is expected to be complex and lengthy, it may be appropriate to consider a staged procedure. 51 
Equipment
Various pieces of equipment can be used to limit haemorrhage, either prophylactically or actively, as follows.
(i) Arterial tourniquets have been shown to be useful in Jehovah's Witnesses undergoing peripheral limb or joint surgery.
51 • Fibrinogen concentrate (if acceptable) 2 g i.v.
• Factor VIII and IX replacement 
Radiological care
Depending on the source of bleeding, interventional radiology can take several forms, including embolization and the insertion of intravascular occlusive balloons. 63 Such balloons have been used to limit bleeding in patients, including Jehovah's Witnesses, 64 in a variety of surgical settings where massive blood loss is a possibility.
Optimization of anaemia tolerance
In addition to the general measures that can be employed to optimize oxygen delivery and consumption (such as supplemental oxygen, intubation, and ventilation), some specific measures are as follows.
Deliberate hypothermia
Mild to moderate hypothermia has been used successfully in Jehovah's Witness patients (in conjucntion with other therapies) [65] [66] [67] by reducing total body oxygen consumption and increasing the dissolved portion of oxygen without impairing oxygen extraction; 68 69 however, temperatures below 35°C have been shown to increase blood loss and transfusion requirements. 70 
Extracorporeal oxygen therapies
Extracorporeal membrane oxygenation and cardiopulmonary bypass act as a means of providing circulatory (flow) and respiratory support (gaseous exchange). Their successful use has been described in Jehovah's Witnesses, although these have tended to be in elective surgery or in patients with respiratory failure and acceptable haemoglobin. 71 72 Use in the critically ill and severely anaemic Jehovah's Witness has not been fully established.
Hyperbaric oxygen therapy
Hyperbaric oxygen therapy remains a treatment option in patients with profound hypoxia, and its successful intermittent use during a patient episode has been described in severely anaemic Jehovah's Witnesses. 73 In addition to the limited number of sites, hyperbaric oxygen therapy presents other problems, the main one being the logistics of transferring a critically ill patient between critical care units and the chamber. Other problems include organization; most hyperbaric oxygen therapy centres are not adequately set up to deal with critically ill patients, and the intervention itself is not entirely benign. 74 
Red cell substitutes
The WTS literature calls these 'a potential quality alternative to blood transfusion'; 75 Other novel agents are currently in preclinical trials, including dendrimers and porphryin-based oxygen carriers. 83 
Enhancement of haemoglobin concentration and red blood cell production
Anaemia is usually caused by one of three processes: acute blood loss, decreased or faulty red cell production, or red cell destruction. Anaemia is a risk factor for increased morbidity and mortality in a variety of patient types. [84] [85] [86] When seen before surgery, it is a predictor for allogeneic transfusion. 87 In the context of capacity, some studies purport that even mild anaemia may be independently associated with impaired cognition in the elderly. 88 Although one small study of medical students showed that lower Hb concentrations were associated with lower mini-mental state examination scores, the effects in the rest of the population at large or the concept of a critical Hb concentration for sound cognition have not been investigated or confirmed. 89 Anaemia tolerance is a key principle in managing low Hb in Jehovah's Witnesses. Weiskopf , Spence and colleagues 95 demonstrated that below 50 g litre −1 , Hb concentration becomes an independent predictor of mortality. In either instance ( preoperative or postoperative), haemoglobin synthesis and erythropoiesis are intrinsically linked, and erythropoiesis-stimulating agents and the key substrates (iron, vitamin B 12 , and folate) must be co-administered in order to work effectively. 96 Iron, vitamin B 12 , and folate Before surgery, either oral or i.v. iron can be used; however, i.v. iron produces a more rapid and reliable increase in Hb concentrations. 97 This is especially true in inflammatory states, where hepcidin (the hormone responsible for iron homeostasis) inhibits gut iron uptake and mobilization from storage sites. 98 Parenteral iron preparations consist of iron and chemically modified carbohydrates. We outline commonly used agents in Table 4 . The effect of i.v. iron on erthyropoiesis may only last up to 10 days, 97 and patients may require repeated doses for preoperative optimization. Despite many studies demonstrating its safety in a variety of clinical scenarios, there are still concerns regarding the relatively low incidence of severe hypersensitivity reactions. 99 Vitamin B 12 and folate should also be replaced if a preoperative deficiency is identified. After surgery, the inflammatory component of the surgical stress response induces ferritin synthesis (regardless of total body iron stores) 100 and reduces transferrin and serum iron concentrations. These actions will reduce oral iron absorption; hence i.v. iron is the preferred option. Vitamin B 12 and folate are innocuous agents, and while there is little evidence to suggest significant benefit in the acute setting, the potential benefits are likely to outweigh any potential risk of administration.
Recombinant erythropoietin
Recombinant erythropoietin is the most frequently used erythropoiesis-stimulating agent. It was first used in the treatment of anaemia secondary to end-stage renal disease. 101 Recombinant erythropoietin acts by stimulating the following: (i) proliferation and differentiation of erythroid precursors to increase immature erythrocyte production; (ii) release of erythrocytes from bone marrow; and (iii) Hb production. 102 It may also protect cells by inhibiting various protein kinase cascades while increasing stem cell recruitment into damaged areas, 103 and has plateletactivating effects. The effects of recombinant erythropoietins are partly governed by ferritin, transferrin, iron, vitamin B 12 , and folic acid concentrations. 104 Before surgery, it is important to check which recombinant erythropoietin preparation is being used because some do contain trace amounts of human albumin, 102 which may conflict with the beliefs of some Jehovah's Witnesses. The response appears to be dose dependent, 105 106 with an increase in reticulocyte count 107 being seen within 10 days and new erythropoiesis within 1-6 weeks. 101 Preoperative regimens are either a single dose of 300 µg (at an approximate cost of £180 per dose) or multidose regimens, with a number of studies having used as much as 600 µg kg −1 weekly for 3-4 weeks. 107 After surgery, there is a transient erythropoietin deficiency, which prevents an immediate response in erythrocyte production. 100 Postoperative regimens shown to be successful are also variable, including the following: (i) 600 µg kg −1 daily for Preferably diluted in 10-20 ml 109 110 Correction of coagulation defects and promotion of haemostasis
The treatment of coagulopathy and promotion of haemostasis largely depend on whether the setting is elective or emergent.
In both cases, therapy should be guided by coagulation tests (laboratory based or ideally point of care, e.g. thromboelastography (TEG) or thromboelastometry (ROTEM)), and early discussion with a haematologist is warranted both before and after surgery. While management in the elective setting can be more considered, the acute setting requires an aggressive and comprehensive strategy, with replacement of multiple elements simultaneously rather than piecemeal. Before surgery, the first management step is to stop any drugs (e.g. non-steroidal anti-inflammatory drugs or oral anticoagulants) or herbal remedies (e.g. garlic or ginger) that may impair clotting and administer an antidote if appropriate. Any subsequent management depends on the detection of a preoperative abnormality, be it congenital or acquired. Electively, the most commonly used agents are those to correct an inherited coagulopathy and involve either stimulating factor release or production or replacing the factors themselves (it should be noted that any of these agents can or may also be used during or after surgery or in the emergent setting).
Desmopressin is a synthetic analogue of vasopressin. It improves haemostasis by stimulating hepatic release of clotting factor VIII 111 Increasing evidence suggests that it does not improve long-term outcomes and may increase the thromboembolic event rate.
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Another common preoperative scenario is antagonism of anticoagulant drugs, such as warfarin. Vitamin K is essential for the production of clotting factors II, VII, IX, and X and proteins C, S, and Z. 123 129 During and after surgery, the primary concern is arrest of bleeding and clot maintenance. Various studies have shown that aggressive fibrinogen replacement can result in faster, stronger, and better clot formation. 130 The first-line agent is cryoprecipitate, a plasma fraction rich in fibrinogen, von Willebrand Factor, and factor VIII. As it is a minor blood fraction, it may not be acceptable to some Jehovah's Witnesses. The usual dose is 1-2 units per 10 kg body weight or two pools (equivalent to 10 units), which will usually increase fibrinogen concentrations by 1 g litre −1 . 131 132 While cryoprecipitate has been used in several Jehovah's Witness patient case reports (mostly patients undergoing cardiac surgery), 133 in none is it the sole agent used, which makes it difficult to appraise its individual effect. The secondline treatment is fibrinogen concentrate (which may be deemed unacceptable because it is derived from human plasma). Although not currently licensed in the UK, its use is associated with significantly reduced red cell loss and fresh frozen plasma and platelet use, 134 and in massive obstetric haemorrhage an observational study found it to be as efficacious as cryoprecipitate. 135 However, again, there is a paucity of evidence for its individual use in coagulopathy treatment in Jehovah's Witnesses. An initial dose of 1-2 g of fibrinogen concentrate is recommended. 136 Inhibition of fibrinolysis also improves clot formation. Lysine analogues act by binding to fibrin clots and competitively inhibiting plasminogen activation. Tranexamic acid is the agent of choice and is 10 times more potent than ε-aminocaproic acid. Prophylactic and emergency use of tranexamic acid 137 138 is well recognized in many major haemorrhage protocols in Jehovah's Witnesses. Doses of 500-1000 mg i.v. or 10 mg kg −1 every 6 h to a maximal rate of 100 mg min −1 have been shown to be effective. 138 Aprotinin, a direct plasmin inhibitor, also inhibits fibrinolysis and has been used in a variety of surgical specialties, 139 140 not limited to Jehovah's Witness patients. In 2008, the BART study 141 suggested that use was associated with increased mortality. However, the European Medicines Agency's committee for medicinal products for human use recently stated that these findings were unreliable and recommended lifting suspension and, as such, it could be used on a named patient basis. 142 
Summary
Treatment of Jehovah's Witnesses during the past 50 yr has led to a greater awareness of blood conservation and advances in bloodless surgery. Their beliefs regarding blood and transfusion raise various ethical and legal points, knowledge of which is essential. Evidence suggests that while there is no universally 
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